KEGG   PATHWAY: hsa05169Help
Entry
hsa05169                    Pathway                                

Name
Epstein-Barr virus infection - Homo sapiens (human)
Description
Epstein-Barr virus (EBV) is a gamma-herpes virus that widely infects human populations predominantly at an early age but remains mostly asymptomatic. EBV has been linked to a wide spectrum of human malignancies, including nasopharyngeal carcinoma and other hematologic cancers, like Hodgkin's lymphoma, Burkitt's lymphoma (BL), B-cell immunoblastic lymphoma in HIV patients, and posttransplant-associated lymphoproliferative diseases.  EBV has the unique ability to establish life-long latent infection in primary human B lymphocytes. During latent infection, EBV expresses a small subset of genes, including 6 nuclear antigens (EBNA-1, -2, -3A, -3B, -3C, and -LP), 3 latent membrane proteins (LMP-1, -2A, and -2B), 2 small noncoding RNAs (EBER-1 and 2). On the basis of these latent gene expression, three different latency patterns associated with the types of cancers are recognized.
Class
Human Diseases; Infectious diseases: Viral
BRITE hierarchy
Pathway map
hsa05169  Epstein-Barr virus infection
hsa05169

Ortholog table
Network
N00223  EBV EBNA1 to p53-mediated transcription
N00224  EBV EBNALP RBP-Jk-mediated transcription
N00225  EBV EBNA2 to RBP-Jk-mediated transcription
N00226  EBV EBNA3A/3B/3C to RBP-Jk-mediated transcription
N00262  EBV EBNA3C to intrinsic apoptotic pathway
N00263  EBV EBNA3C to p53-mediated transcription
N00264  EBV EBNA3C to p27-Cell cycle G1/S
N00265  EBV LMP1 to NFKB signaling pathway
N00266  EBV LMP2A to PI3K signaling pathway
N00466  EBV BPLF1 to TLR2/4-NFKB signaling pathway
N00467  EBV BPLF1 to TLR2/4-NFKB signaling pathway
N00468  EBV BPLF1 to TLR2/4-NFKB signaling pathway
N00470  EBV BGLF4 to RIG-I-like receptor signaling pathway
N00471  EBV LMP2A/2B to IFN signaling pathway
N00472  EBV LMP1 to IFN signaling pathway
N00473  EBV BGLF4 to IFN signaling pathway
N00474  EBV BHRF1 to intrinsic apoptotic pathway
N00475  EBV BHRF1 to intrinsic apoptotic pathway
N00476  EBV BHRF1 to intrinsic apoptotic pathway
N00477  EBV BHRF1 to crosstalk between extrinsic and intrinsic apoptotic pathways
N00478  EBV BARF1 to intrinsic apoptotic pathway
N00479  EBV BNLF2a to antigen processing and presentation by MHC class I molecules
N00480  EBV BILF1 to antigen processing and presentation by MHC class I molecules
N00481  EBV BZLF1 to p53-mediated transcription
N00482  EBV EBNA3C to p27-Cell cycle G1/S
N00483  EBV EBNA3C to p21-cell cycle G1/S
N00484  EBV EBNA3C to p21-cell cycle G1/S
N00485  EBV LMP1 to PI3K signaling pathway
N00486  EBV LMP1 to Jak-STAT signaling pathway
N00488  EBV LMP2A to BCR signaling pathway
 » show all
Disease
H00007  Hodgkin lymphoma
H00008  Burkitt lymphoma
H00054  Nasopharyngeal cancer
H00367  Infectious mononucleosis
Organism
Homo sapiens (human) [GN:hsa]
Gene
1380  CR2; complement C3d receptor 2 [KO:K04012]
930  CD19; CD19 molecule [KO:K06465]
3108  HLA-DMA; major histocompatibility complex, class II, DM alpha [KO:K06752]
3109  HLA-DMB; major histocompatibility complex, class II, DM beta [KO:K06752]
3111  HLA-DOA; major histocompatibility complex, class II, DO alpha [KO:K06752]
3112  HLA-DOB; major histocompatibility complex, class II, DO beta [KO:K06752]
3113  HLA-DPA1; major histocompatibility complex, class II, DP alpha 1 [KO:K06752]
3115  HLA-DPB1; major histocompatibility complex, class II, DP beta 1 [KO:K06752]
3117  HLA-DQA1; major histocompatibility complex, class II, DQ alpha 1 [KO:K06752]
3118  HLA-DQA2; major histocompatibility complex, class II, DQ alpha 2 [KO:K06752]
3119  HLA-DQB1; major histocompatibility complex, class II, DQ beta 1 [KO:K06752]
3122  HLA-DRA; major histocompatibility complex, class II, DR alpha [KO:K06752]
3123  HLA-DRB1; major histocompatibility complex, class II, DR beta 1 [KO:K06752]
3125  HLA-DRB3; major histocompatibility complex, class II, DR beta 3 [KO:K06752]
3126  HLA-DRB4; major histocompatibility complex, class II, DR beta 4 [KO:K06752]
3127  HLA-DRB5; major histocompatibility complex, class II, DR beta 5 [KO:K06752]
7097  TLR2; toll like receptor 2 [KO:K10159]
4615  MYD88; MYD88, innate immune signal transduction adaptor [KO:K04729]
51135  IRAK4; interleukin 1 receptor associated kinase 4 [KO:K04733] [EC:2.7.11.1]
3654  IRAK1; interleukin 1 receptor associated kinase 1 [KO:K04730] [EC:2.7.11.1]
7189  TRAF6; TNF receptor associated factor 6 [KO:K03175] [EC:2.3.2.27]
10454  TAB1; TGF-beta activated kinase 1 (MAP3K7) binding protein 1 [KO:K04403]
23118  TAB2; TGF-beta activated kinase 1 (MAP3K7) binding protein 2 [KO:K04404]
6885  MAP3K7; mitogen-activated protein kinase kinase kinase 7 [KO:K04427] [EC:2.7.11.25]
1147  CHUK; conserved helix-loop-helix ubiquitous kinase [KO:K04467] [EC:2.7.11.10]
3551  IKBKB; inhibitor of nuclear factor kappa B kinase subunit beta [KO:K07209] [EC:2.7.11.10]
8517  IKBKG; inhibitor of nuclear factor kappa B kinase subunit gamma [KO:K07210]
4792  NFKBIA; NFKB inhibitor alpha [KO:K04734]
4790  NFKB1; nuclear factor kappa B subunit 1 [KO:K02580]
5970  RELA; RELA proto-oncogene, NF-kB subunit [KO:K04735]
7124  TNF; tumor necrosis factor [KO:K03156]
3569  IL6; interleukin 6 [KO:K05405]
23586  DDX58; DExD/H-box helicase 58 [KO:K12646] [EC:3.6.4.13]
57506  MAVS; mitochondrial antiviral signaling protein [KO:K12648]
7187  TRAF3; TNF receptor associated factor 3 [KO:K03174]
29110  TBK1; TANK binding kinase 1 [KO:K05410] [EC:2.7.11.10]
9641  IKBKE; inhibitor of nuclear factor kappa B kinase subunit epsilon [KO:K07211] [EC:2.7.11.10]
3665  IRF7; interferon regulatory factor 7 [KO:K09447]
3661  IRF3; interferon regulatory factor 3 [KO:K05411]
3439  IFNA1; interferon alpha 1 [KO:K05414]
3440  IFNA2; interferon alpha 2 [KO:K05414]
3441  IFNA4; interferon alpha 4 [KO:K05414]
3442  IFNA5; interferon alpha 5 [KO:K05414]
3443  IFNA6; interferon alpha 6 [KO:K05414]
3444  IFNA7; interferon alpha 7 [KO:K05414]
3445  IFNA8; interferon alpha 8 [KO:K05414]
3446  IFNA10; interferon alpha 10 [KO:K05414]
3447  IFNA13; interferon alpha 13 [KO:K05414]
3448  IFNA14; interferon alpha 14 [KO:K05414]
3449  IFNA16; interferon alpha 16 [KO:K05414]
3451  IFNA17; interferon alpha 17 [KO:K05414]
3452  IFNA21; interferon alpha 21 [KO:K05414]
3456  IFNB1; interferon beta 1 [KO:K05415]
3454  IFNAR1; interferon alpha and beta receptor subunit 1 [KO:K05130]
3455  IFNAR2; interferon alpha and beta receptor subunit 2 [KO:K05131]
3716  JAK1; Janus kinase 1 [KO:K11217] [EC:2.7.10.2]
7297  TYK2; tyrosine kinase 2 [KO:K11219] [EC:2.7.10.2]
6772  STAT1; signal transducer and activator of transcription 1 [KO:K11220]
6773  STAT2; signal transducer and activator of transcription 2 [KO:K11221]
10379  IRF9; interferon regulatory factor 9 [KO:K04693]
5610  EIF2AK2; eukaryotic translation initiation factor 2 alpha kinase 2 [KO:K16195] [EC:2.7.11.1]
4938  OAS1; 2'-5'-oligoadenylate synthetase 1 [KO:K14216] [EC:2.7.7.84]
4939  OAS2; 2'-5'-oligoadenylate synthetase 2 [KO:K14216] [EC:2.7.7.84]
4940  OAS3; 2'-5'-oligoadenylate synthetase 3 [KO:K14216] [EC:2.7.7.84]
3627  CXCL10; C-X-C motif chemokine ligand 10 [KO:K12671]
9636  ISG15; ISG15 ubiquitin-like modifier [KO:K12159]
355  FAS; Fas cell surface death receptor [KO:K04390]
8772  FADD; Fas associated via death domain [KO:K02373]
841  CASP8; caspase 8 [KO:K04398] [EC:3.4.22.61]
637  BID; BH3 interacting domain death agonist [KO:K04726]
10018  BCL2L11; BCL2 like 11 [KO:K16341]
596  BCL2; BCL2, apoptosis regulator [KO:K02161]
581  BAX; BCL2 associated X, apoptosis regulator [KO:K02159]
578  BAK1; BCL2 antagonist/killer 1 [KO:K14021]
54205  CYCS; cytochrome c, somatic [KO:K08738]
317  APAF1; apoptotic peptidase activating factor 1 [KO:K02084]
842  CASP9; caspase 9 [KO:K04399] [EC:3.4.22.62]
836  CASP3; caspase 3 [KO:K02187] [EC:3.4.22.56]
916  CD3E; CD3e molecule [KO:K06451]
917  CD3G; CD3g molecule [KO:K06452]
915  CD3D; CD3d molecule [KO:K06450]
919  CD247; CD247 molecule [KO:K06453]
5701  PSMC2; proteasome 26S subunit, ATPase 2 [KO:K03061]
5700  PSMC1; proteasome 26S subunit, ATPase 1 [KO:K03062]
5704  PSMC4; proteasome 26S subunit, ATPase 4 [KO:K03063]
5706  PSMC6; proteasome 26S subunit, ATPase 6 [KO:K03064]
5702  PSMC3; proteasome 26S subunit, ATPase 3 [KO:K03065]
5705  PSMC5; proteasome 26S subunit, ATPase 5 [KO:K03066]
5708  PSMD2; proteasome 26S subunit, non-ATPase 2 [KO:K03028]
5707  PSMD1; proteasome 26S subunit, non-ATPase 1 [KO:K03032]
5709  PSMD3; proteasome 26S subunit, non-ATPase 3 [KO:K03033]
5718  PSMD12; proteasome 26S subunit, non-ATPase 12 [KO:K03035]
5717  PSMD11; proteasome 26S subunit, non-ATPase 11 [KO:K03036]
9861  PSMD6; proteasome 26S subunit, non-ATPase 6 [KO:K03037]
5713  PSMD7; proteasome 26S subunit, non-ATPase 7 [KO:K03038]
5719  PSMD13; proteasome 26S subunit, non-ATPase 13 [KO:K03039]
5710  PSMD4; proteasome 26S subunit, non-ATPase 4 [KO:K03029]
10213  PSMD14; proteasome 26S subunit, non-ATPase 14 [KO:K03030]
5714  PSMD8; proteasome 26S subunit, non-ATPase 8 [KO:K03031]
11047  ADRM1; adhesion regulating molecule 1 [KO:K06691]
7979  SEM1; SEM1, 26S proteasome complex subunit [KO:K10881]
6890  TAP1; transporter 1, ATP binding cassette subfamily B member [KO:K05653]
6891  TAP2; transporter 2, ATP binding cassette subfamily B member [KO:K05654]
6892  TAPBP; TAP binding protein [KO:K08058]
2923  PDIA3; protein disulfide isomerase family A member 3 [KO:K08056] [EC:5.3.4.1]
811  CALR; calreticulin [KO:K08057]
3105  HLA-A; major histocompatibility complex, class I, A [KO:K06751]
3106  HLA-B; major histocompatibility complex, class I, B [KO:K06751]
3107  HLA-C; major histocompatibility complex, class I, C [KO:K06751]
3134  HLA-F; major histocompatibility complex, class I, F [KO:K06751]
3135  HLA-G; major histocompatibility complex, class I, G [KO:K06751]
3133  HLA-E; major histocompatibility complex, class I, E [KO:K06751]
567  B2M; beta-2-microglobulin [KO:K08055]
22938  SNW1; SNW domain containing 1 [KO:K06063]
25942  SIN3A; SIN3 transcription regulator family member A [KO:K11644]
3065  HDAC1; histone deacetylase 1 [KO:K06067] [EC:3.5.1.98]
3066  HDAC2; histone deacetylase 2 [KO:K06067] [EC:3.5.1.98]
9612  NCOR2; nuclear receptor corepressor 2 [KO:K06065]
8819  SAP30; Sin3A associated protein 30 [KO:K19202]
9541  CIR1; corepressor interacting with RBPJ, 1 [KO:K06066]
11317  RBPJL; recombination signal binding protein for immunoglobulin kappa J region like [KO:K06053]
3516  RBPJ; recombination signal binding protein for immunoglobulin kappa J region [KO:K06053]
3280  HES1; hes family bHLH transcription factor 1 [KO:K06054]
2208  FCER2; Fc fragment of IgE receptor II [KO:K06468]
864  RUNX3; runt related transcription factor 3 [KO:K09279]
4609  MYC; MYC proto-oncogene, bHLH transcription factor [KO:K04377]
7874  USP7; ubiquitin specific peptidase 7 [KO:K11838] [EC:3.4.19.12]
4193  MDM2; MDM2 proto-oncogene [KO:K06643] [EC:2.3.2.27]
7157  TP53; tumor protein p53 [KO:K04451]
1026  CDKN1A; cyclin dependent kinase inhibitor 1A [KO:K06625]
1647  GADD45A; growth arrest and DNA damage inducible alpha [KO:K04402]
4616  GADD45B; growth arrest and DNA damage inducible beta [KO:K04402]
10912  GADD45G; growth arrest and DNA damage inducible gamma [KO:K04402]
1643  DDB2; damage specific DNA binding protein 2 [KO:K10140]
51426  POLK; DNA polymerase kappa [KO:K03511] [EC:2.7.7.7]
7188  TRAF5; TNF receptor associated factor 5 [KO:K09849]
5290  PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922] [EC:2.7.1.153]
5293  PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922] [EC:2.7.1.153]
5291  PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922] [EC:2.7.1.153]
5295  PIK3R1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649]
5296  PIK3R2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649]
8503  PIK3R3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649]
207  AKT1; AKT serine/threonine kinase 1 [KO:K04456] [EC:2.7.11.1]
208  AKT2; AKT serine/threonine kinase 2 [KO:K04456] [EC:2.7.11.1]
10000  AKT3; AKT serine/threonine kinase 3 [KO:K04456] [EC:2.7.11.1]
9020  MAP3K14; mitogen-activated protein kinase kinase kinase 14 [KO:K04466] [EC:2.7.11.25]
5971  RELB; RELB proto-oncogene, NF-kB subunit [KO:K09253]
4791  NFKB2; nuclear factor kappa B subunit 2 [KO:K04469]
8717  TRADD; TNFRSF1A associated via death domain [KO:K03171]
4793  NFKBIB; NFKB inhibitor beta [KO:K02581]
4794  NFKBIE; NFKB inhibitor epsilon [KO:K05872]
6416  MAP2K4; mitogen-activated protein kinase kinase 4 [KO:K04430] [EC:2.7.12.2]
5609  MAP2K7; mitogen-activated protein kinase kinase 7 [KO:K04431] [EC:2.7.12.2]
5599  MAPK8; mitogen-activated protein kinase 8 [KO:K04440] [EC:2.7.11.24]
5602  MAPK10; mitogen-activated protein kinase 10 [KO:K04440] [EC:2.7.11.24]
5601  MAPK9; mitogen-activated protein kinase 9 [KO:K04440] [EC:2.7.11.24]
7186  TRAF2; TNF receptor associated factor 2 [KO:K03173] [EC:2.3.2.27]
8737  RIPK1; receptor interacting serine/threonine kinase 1 [KO:K02861] [EC:2.7.11.1]
5606  MAP2K3; mitogen-activated protein kinase kinase 3 [KO:K04432] [EC:2.7.12.2]
5608  MAP2K6; mitogen-activated protein kinase kinase 6 [KO:K04433] [EC:2.7.12.2]
5600  MAPK11; mitogen-activated protein kinase 11 [KO:K04441] [EC:2.7.11.24]
6300  MAPK12; mitogen-activated protein kinase 12 [KO:K04441] [EC:2.7.11.24]
5603  MAPK13; mitogen-activated protein kinase 13 [KO:K04441] [EC:2.7.11.24]
1432  MAPK14; mitogen-activated protein kinase 14 [KO:K04441] [EC:2.7.11.24]
3725  JUN; Jun proto-oncogene, AP-1 transcription factor subunit [KO:K04448]
956  ENTPD3; ectonucleoside triphosphate diphosphohydrolase 3 [KO:K01510] [EC:3.6.1.5]
377841  ENTPD8; ectonucleoside triphosphate diphosphohydrolase 8 [KO:K01510] [EC:3.6.1.5]
953  ENTPD1; ectonucleoside triphosphate diphosphohydrolase 1 [KO:K01510] [EC:3.6.1.5]
958  CD40; CD40 molecule [KO:K03160]
960  CD44; CD44 molecule (Indian blood group) [KO:K06256]
3683  ITGAL; integrin subunit alpha L [KO:K05718]
965  CD58; CD58 molecule [KO:K06492]
3383  ICAM1; intercellular adhesion molecule 1 [KO:K06490]
7431  VIM; vimentin [KO:K07606]
7128  TNFAIP3; TNF alpha induced protein 3 [KO:K11859] [EC:3.4.19.12]
3718  JAK3; Janus kinase 3 [KO:K11218] [EC:2.7.10.2]
6774  STAT3; signal transducer and activator of transcription 3 [KO:K04692]
4067  LYN; LYN proto-oncogene, Src family tyrosine kinase [KO:K05854] [EC:2.7.10.2]
6850  SYK; spleen associated tyrosine kinase [KO:K05855] [EC:2.7.10.2]
4734  NEDD4; neural precursor cell expressed, developmentally down-regulated 4, E3 ubiquitin protein ligase [KO:K10591] [EC:2.3.2.26]
5879  RAC1; Rac family small GTPase 1 [KO:K04392]
102723407  IGH; immunoglobulin heavy variable 4-38-2-like [KO:K06856]
695  BTK; Bruton tyrosine kinase [KO:K07370] [EC:2.7.10.2]
29760  BLNK; B cell linker [KO:K07371]
5336  PLCG2; phospholipase C gamma 2 [KO:K05859] [EC:3.1.4.11]
6502  SKP2; S-phase kinase associated protein 2 [KO:K03875]
1027  CDKN1B; cyclin dependent kinase inhibitor 1B [KO:K06624]
595  CCND1; cyclin D1 [KO:K04503]
894  CCND2; cyclin D2 [KO:K10151]
896  CCND3; cyclin D3 [KO:K10152]
1019  CDK4; cyclin dependent kinase 4 [KO:K02089] [EC:2.7.11.22]
1021  CDK6; cyclin dependent kinase 6 [KO:K02091] [EC:2.7.11.22]
890  CCNA2; cyclin A2 [KO:K06627]
8900  CCNA1; cyclin A1 [KO:K06627]
898  CCNE1; cyclin E1 [KO:K06626]
9134  CCNE2; cyclin E2 [KO:K06626]
1017  CDK2; cyclin dependent kinase 2 [KO:K02206] [EC:2.7.11.22]
5925  RB1; RB transcriptional corepressor 1 [KO:K06618]
1869  E2F1; E2F transcription factor 1 [KO:K17454]
1870  E2F2; E2F transcription factor 2 [KO:K09389]
1871  E2F3; E2F transcription factor 3 [KO:K06620]
Compound
C00076  Calcium cation
C01245  D-myo-Inositol 1,4,5-trisphosphate
C05981  Phosphatidylinositol-3,4,5-trisphosphate
Reference
  Authors
Young LS, Rickinson AB.
  Title
Epstein-Barr virus: 40 years on.
  Journal
Nat Rev Cancer 4:757-68 (2004)
DOI:10.1038/nrc1452
Reference
  Authors
Saha A, Robertson ES
  Title
Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes.
  Journal
Clin Cancer Res 17:3056-63 (2011)
DOI:10.1158/1078-0432.CCR-10-2578
Reference
  Authors
Ning S
  Title
Innate immune modulation in EBV infection.
  Journal
Herpesviridae 2:1 (2011)
DOI:10.1186/2042-4280-2-1
Reference
  Authors
Stanfield BA, Luftig MA
  Title
Recent advances in understanding Epstein-Barr virus.
  Journal
F1000Res 6:386 (2017)
DOI:10.12688/f1000research.10591.1
Reference
  Authors
van Gent M, Braem SG, de Jong A, Delagic N, Peeters JG, Boer IG, Moynagh PN, Kremmer E, Wiertz EJ, Ovaa H, Griffin BD, Ressing ME
  Title
Epstein-Barr virus large tegument protein BPLF1 contributes to innate immune evasion through interference with toll-like receptor signaling.
  Journal
PLoS Pathog 10:e1003960 (2014)
DOI:10.1371/journal.ppat.1003960
Reference
  Authors
Rajsbaum R, Garcia-Sastre A
  Title
Viral evasion mechanisms of early antiviral responses involving regulation of ubiquitin pathways.
  Journal
Trends Microbiol 21:421-9 (2013)
DOI:10.1016/j.tim.2013.06.006
Reference
  Authors
Hoffmann HH, Schneider WM, Rice CM
  Title
Interferons and viruses: an evolutionary arms race of molecular interactions.
  Journal
Trends Immunol 36:124-38 (2015)
DOI:10.1016/j.it.2015.01.004
Reference
  Authors
Spender LC, Inman GJ
  Title
Inhibition of germinal centre apoptotic programmes by epstein-barr virus.
  Journal
Adv Hematol 2011:829525 (2011)
DOI:10.1155/2011/829525
Reference
  Authors
Fu Q, He C, Mao ZR
  Title
Epstein-Barr virus interactions with the Bcl-2 protein family and apoptosis in human tumor cells.
  Journal
J Zhejiang Univ Sci B 14:8-24 (2013)
DOI:10.1631/jzus.B1200189
Reference
  Authors
Wang Y, Banerjee S, Ding L, Cai C, Wei F, Cai Q
  Title
The regulatory role of protein phosphorylation in human gammaherpesvirus associated cancers.
  Journal
Virol Sin 32:357-368 (2017)
DOI:10.1007/s12250-017-4081-9
Reference
  Authors
Melchjorsen J
  Title
Learning from the messengers: innate sensing of viruses and cytokine regulation of immunity - clues for treatments and vaccines.
  Journal
Viruses 5:470-527 (2013)
DOI:10.3390/v5020470
Reference
  Authors
Hansen TH, Bouvier M
  Title
MHC class I antigen presentation: learning from viral evasion strategies.
  Journal
Nat Rev Immunol 9:503-13 (2009)
DOI:10.1038/nri2575
Reference
  Authors
Ressing ME, Horst D, Griffin BD, Tellam J, Zuo J, Khanna R, Rowe M, Wiertz EJ
  Title
Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
  Journal
Semin Cancer Biol 18:397-408 (2008)
DOI:10.1016/j.semcancer.2008.10.008
Reference
  Authors
Horst D, Verweij MC, Davison AJ, Ressing ME, Wiertz EJ
  Title
Viral evasion of T cell immunity: ancient mechanisms offering new applications.
  Journal
Curr Opin Immunol 23:96-103 (2011)
DOI:10.1016/j.coi.2010.11.005
Reference
  Authors
Ghosh Roy S, Robertson ES, Saha A
  Title
Epigenetic Impact on EBV Associated B-Cell Lymphomagenesis.
  Journal
Biomolecules 6:E46 (2016)
DOI:10.3390/biom6040046
Reference
  Authors
Dawson CW, Port RJ, Young LS
  Title
The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC).
  Journal
Semin Cancer Biol 22:144-53 (2012)
DOI:10.1016/j.semcancer.2012.01.004
Reference
  Authors
Cai Q, Chen K, Young KH
  Title
Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders.
  Journal
Exp Mol Med 47:e133 (2015)
DOI:10.1038/emm.2014.105
Reference
  Authors
Zheng H, Li LL, Hu DS, Deng XY, Cao Y
  Title
Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma.
  Journal
Cell Mol Immunol 4:185-96 (2007)
Reference
  Authors
Ersing I, Bernhardt K, Gewurz BE
  Title
NF-kappaB and IRF7 pathway activation by Epstein-Barr virus Latent Membrane Protein 1.
  Journal
Viruses 5:1587-606 (2013)
DOI:10.3390/v5061587
Reference
  Authors
Wang LW, Jiang S, Gewurz BE
  Title
Epstein-Barr Virus LMP1-Mediated Oncogenicity.
  Journal
J Virol 91:e01718-16 (2017)
DOI:10.1128/JVI.01718-16
Reference
  Authors
Mori N, Morishita M, Tsukazaki T, Yamamoto N
  Title
Repression of Smad-dependent transforming growth factor-beta signaling by Epstein-Barr virus latent membrane protein 1 through nuclear factor-kappaB.
  Journal
Int J Cancer 105:661-8 (2003)
DOI:10.1002/ijc.11146
Reference
  Authors
Edwards RH, Marquitz AR, Raab-Traub N
  Title
Changes in expression induced by Epstein-Barr Virus LMP1-CTAR1: potential role of bcl3.
  Journal
MBio 6:e00441-15 (2015)
DOI:10.1128/mBio.00441-15
Reference
  Authors
Thorley-Lawson DA
  Title
Epstein-Barr virus: exploiting the immune system.
  Journal
Nat Rev Immunol 1:75-82 (2001)
DOI:10.1038/35095584
Reference
  Authors
Eliopoulos AG, Young LS
  Title
LMP1 structure and signal transduction.
  Journal
Semin Cancer Biol 11:435-44 (2001)
DOI:10.1006/scbi.2001.0410
Reference
  Authors
Holowaty MN, Sheng Y, Nguyen T, Arrowsmith C, Frappier L
  Title
Protein interaction domains of the ubiquitin-specific protease, USP7/HAUSP.
  Journal
J Biol Chem 278:47753-61 (2003)
DOI:10.1074/jbc.M307200200
Reference
  Authors
Kang H, Kiess A, Chung CH
  Title
Emerging biomarkers in head and neck cancer in the era of genomics.
  Journal
Nat Rev Clin Oncol 12:11-26 (2015)
DOI:10.1038/nrclinonc.2014.192
Reference
  Authors
Tornesello ML, Annunziata C, Tornesello AL, Buonaguro L, Buonaguro FM
  Title
Human Oncoviruses and p53 Tumor Suppressor Pathway Deregulation at the Origin of Human Cancers.
  Journal
Cancers (Basel) 10:E213 (2018)
DOI:10.3390/cancers10070213
Reference
  Authors
Sato Y, Kamura T, Shirata N, Murata T, Kudoh A, Iwahori S, Nakayama S, Isomura H, Nishiyama Y, Tsurumi T
  Title
Degradation of phosphorylated p53 by viral protein-ECS E3 ligase complex.
  Journal
PLoS Pathog 5:e1000530 (2009)
DOI:10.1371/journal.ppat.1000530
Reference
  Authors
Saha A, Murakami M, Kumar P, Bajaj B, Sims K, Robertson ES
  Title
Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2.
  Journal
J Virol 83:4652-69 (2009)
DOI:10.1128/JVI.02408-08
Reference
  Authors
Yi F, Saha A, Murakami M, Kumar P, Knight JS, Cai Q, Choudhuri T, Robertson ES
  Title
Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities.
  Journal
Virology 388:236-47 (2009)
DOI:10.1016/j.virol.2009.03.027
Reference
  Authors
Kumar P, Murakami M, Kaul R, Saha A, Cai Q, Robertson ES
  Title
Deregulation of the cell cycle machinery by Epstein-Barr virus nuclear antigen 3C.
  Journal
Future Virol 4:79-91 (2009)
DOI:10.2217/17460794.4.1.79
Reference
  Authors
Longnecker R
  Title
Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?
  Journal
Adv Cancer Res 79:175-200 (2000)
Reference
  Authors
El-Sharkawy A, Al Zaidan L, Malki A
  Title
Epstein-Barr Virus-Associated Malignancies: Roles of Viral Oncoproteins in Carcinogenesis.
  Journal
Front Oncol 8:265 (2018)
DOI:10.3389/fonc.2018.00265
Reference
  Authors
Dolcetti R, Masucci MG
  Title
Epstein-Barr virus: induction and control of cell transformation.
  Journal
J Cell Physiol 196:207-18 (2003)
DOI:10.1002/jcp.10263
Reference
  Authors
Saha A, Halder S, Upadhyay SK, Lu J, Kumar P, Murakami M, Cai Q, Robertson ES
  Title
Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1.
  Journal
PLoS Pathog 7:e1001275 (2011)
DOI:10.1371/journal.ppat.1001275
KO pathway
ko05169   

DBGET integrated database retrieval system